Idecabtagene vicleucel vs Zevorcabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
Reported efficacy
Progression-free survival (PFS): PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001) (met)
Result source: NCT03651128
Zevorcabtagene autoleucel
Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners
NCT03975907 · Phase 1/2 · status unknown
This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).
Reported efficacy
Phase 1, Safety and tolerability: dose limiting toxicity (28days post administration of CAR-T-cells); Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate (3 months post administration of CAR-T-cells): LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). (met)
Result source: NCT03975907
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Idecabtagene vicleucel | Zevorcabtagene autoleucel |
|---|---|---|
| PFS, median | 8.9bNCT03361748 | —Not reported |
| OS, median | 28.3bNCT03361748 | —Not reported |
| ORR | 74.5%bNCT03361748 | —Not reported |
| VGPR or better | —Not posted · NCT03651128 | —Not reported |
| MRD negativity | —Not posted · NCT03651128 | —Not reported |
PFS, median
- Idecabtagene vicleucel
- 8.9bNCT03361748
- Zevorcabtagene autoleucel
- —Not reported
OS, median
- Idecabtagene vicleucel
- 28.3bNCT03361748
- Zevorcabtagene autoleucel
- —Not reported
ORR
- Idecabtagene vicleucel
- 74.5%bNCT03361748
- Zevorcabtagene autoleucel
- —Not reported
VGPR or better
- Idecabtagene vicleucel
- —Not posted · NCT03651128
- Zevorcabtagene autoleucel
- —Not reported
MRD negativity
- Idecabtagene vicleucel
- —Not posted · NCT03651128
- Zevorcabtagene autoleucel
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Idecabtagene vicleucel: 3 of 4 rows · Zevorcabtagene autoleucel: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Idecabtagene vicleucel |
|---|---|
| Dropout rate | 73.7%a NCT03361748 · Phase 2 show 1 more result5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT03361748 · Phase 2 show 1 more result— NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 78.8%a NCT03361748 · Phase 2 show 1 more result22.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 1 more resultlymphocyte count decreased 85% neutrophil count decreased 77.5% white blood cell decreased 72.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Idecabtagene vicleucel
show 7 more results
show 7 more results
show 7 more results
show 7 more results
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Idecabtagene vicleucel's landscape · Zevorcabtagene autoleucel's landscape